{"id":"sim0718-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Flu-like symptoms"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Myalgia"}]},"_chembl":{"chemblId":"CHEMBL2108760","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SIM0718 combines human serum albumin with interferon alpha to improve the pharmacokinetic properties and biological activity of interferon. The albumin fusion extends the half-life and reduces immunogenicity while maintaining interferon alpha's ability to activate innate immune responses and inhibit viral replication through JAK-STAT signaling pathways.","oneSentence":"SIM0718 is a recombinant human serum albumin-interferon alpha fusion protein that enhances antiviral and immunomodulatory responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:34:42.233Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B"},{"name":"Chronic hepatitis C"}]},"trialDetails":[{"nctId":"NCT06488755","phase":"PHASE3","title":"SIM0718 Treatment of Asthma Clinical Study","status":"RECRUITING","sponsor":"Simcere Pharmaceutical Co., Ltd","startDate":"2024-07-23","conditions":"Asthma; Eosinophilic","enrollment":418},{"nctId":"NCT06701149","phase":"PHASE1","title":"A Comparative Study of the Pharmacokinetics of SIM0718 Injection in Healthy Adult Subjects in China","status":"NOT_YET_RECRUITING","sponsor":"Simcere Pharmaceutical Co., Ltd","startDate":"2024-11-28","conditions":"Healthy Adult Subjects","enrollment":178},{"nctId":"NCT06477835","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of SIM0718 in Adult and Adolescent Patients With Moderate to Severe Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"Simcere Pharmaceutical Co., Ltd","startDate":"2024-10-15","conditions":"Atopic Dermatitis","enrollment":250}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SIM0718 Injection","genericName":"SIM0718 Injection","companyName":"Simcere Pharmaceutical Co., Ltd","companyId":"simcere-pharmaceutical-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"SIM0718 is a recombinant human serum albumin-interferon alpha fusion protein that enhances antiviral and immunomodulatory responses. Used for Chronic hepatitis B, Chronic hepatitis C.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}